Literature DB >> 166935

Activation of C-type viruses during skin graft rejection in the mouse. Interrelationships between immunostimulation and immunosuppression.

M S Hirsch, D A Ellis, A P Kelly, M R Proffitt, P H Black, A P Monaco, M L Wood.   

Abstract

Both mouse-tropic and zenotropic C-type RNA viruses were activated in BALB/c mice during rejection reactions against skin grafts from mice differing at the major histocompatibility locus (A/J) or sharing this locus (DBA/2). Animals that maintained their skin grafts following immunosuppression with antilymphocyte serum (ALS) or cyclophosphamide had a much higher incidence of virus-positivity than animals that did not receive ALS or cyclophosphamide, or that rejected their skin grafts despite immunosuppressive therapy. ALS itself activated type-C viruses from a small proportion of BALB/c mice whereas cyclophoshamide alone did not. Type C viruses were detected in spleens and regional nodes draining skin-graft sites between 1 and 2 weeks following transplantation; thereafter they reached maximum titers in spleens. Viruses were not detected at skin-graft sites, in tails or in thymuses of grafted animals. Virus activation was associated with splenic histological changes consisting of germinal center formation, diffuse hyperplasia of reticulum cells, depletion of periarteriolar lymphocytes and hyperplasia of red pulp hematopoietic elements.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 166935     DOI: 10.1002/ijc.2910150315

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Mason-Pfizer like virus in kidney grafted patients.

Authors:  L Thiry; S Sprecher-Goldberger; P Vandenbussche; M Bossens; P Vereerstraten; O Hestermans-Medard
Journal:  Med Microbiol Immunol       Date:  1979-01-24       Impact factor: 3.402

2.  Leukaemic liver infiltration in AKR mice prematurely induced by immunization with human or allogeneic liver protein.

Authors:  A E Rowe; B M Cowan; A L Eddleston; A D Thomson
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.